DAIC

MARCH 27, 2025

In 2024, the FDA approved Flyrcado for patients with known or suspected coronary artery disease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. 2023 Oct, 82 (16) 15981610.

Coronary Artery Disease 52

Coronary Artery Disease CMS Innovation Ischemia 52

DAIC

JANUARY 23, 2024

The new code, designated by The American Medical Association ( AMA ), supports FFRCT as the standard of care in assessing patients with suspected coronary artery disease ( CAD ). In the hospital setting, CMS increased payment for the FFRCT service by ~7% for 2024.

Reimbursement 105

Reimbursement Coronary Artery Disease CMS Technology 105

DAIC

MARCH 7, 2024

I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronary artery disease, we expect to see this trend really impact the way CT is used in the future.” “The CT procedural mix is evolving, and cardiac CT is starting to account for a large proportion of that.

Technology 111

Technology Document Cardiovascular Imaging Cancer 111

DAIC

MARCH 3, 2025

25, 2025 GE HealthCare has delivered the first patient doses of Flyrcado(flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD), at early adopter imaging centers in the US. tim.hodson Mon, 03/03/2025 - 16:07 Feb.

Coronary Artery Disease 52

Coronary Artery Disease Ischemia Exercise Hospital 52